Skip to Content

Experimental Drug for Alzheimer Disease Shows Promise

TUESDAY, Jan. 12, 2021 -- Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer disease drug called donanemab.

The two-year, phase 2 clinical trial included 272 patients with mild-to-moderate Alzheimer disease symptoms. The company said that patients who received the drug by infusion every four weeks had a 32 percent slower rate of mental decline than those who were given a placebo, The New York Times reported. After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques that are hallmarks of Alzheimer disease, according to Daniel Skovronsky, M.D., the company's chief scientific officer.

However, the findings have not been reviewed by other researchers and have not been published in any form, The Times reported. The main side effect was one often seen in patients who take experimental monoclonal antibodies to treat Alzheimer disease: an accumulation of fluid in the brain. It occurred in close to 30 percent of patients, Skovronsky said, but most had no symptoms. The effect was seen on brain imaging.

The trial findings need to be replicated, Michael Weiner, M.D., a leading Alzheimer disease researcher at the University of California, San Francisco, told The Times. Even so, "this is big news" and "holds out hope for patients and their families," Weiner added.

The New York Times Article

© 2021 HealthDay. All rights reserved.

Posted: January 2021

Read this next

Memory Preserved in Rare Aphasia Tied to Alzheimer Disease

FRIDAY, Jan. 15, 2021 -- Individuals with primary progressive aphasia (PPA) associated with Alzheimer disease (AD) have longitudinally preserved episodic memory, according to a...

Middle-Age Sleep Patterns Tied to Subsequent Cognitive Decline

MONDAY, Dec. 28, 2020 -- Longer time to fall asleep is associated with greater subsequent cognitive decline among middle-aged Hispanic adults, according to a study published...

Good CV Health Metrics From Midlife May Lower Dementia Risk

WEDNESDAY, Dec. 16, 2020 -- Having an ideal or intermediate level of global cardiovascular health (CVH) metrics from midlife to later in life is associated with a reduced risk for...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.